Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ATG7 | O95352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607879 | 0.86 | ADORA1 (0.42) | L3MBTL1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL15607880 | 0.84 | CA1 (0.38) | CA1CA2CA4CA9 | |
| SCHEMBL16367403 | 0.84 | L3MBTL1 (0.38) | L3MBTL1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL15607868 | 0.83 | L3MBTL1 (0.41) | L3MBTL1ADORA1CA1CA2CA4 | |
| SCHEMBL15607808 | 0.83 | EGFR (0.42) | CA1CA2CA9ATG7 | |
| SCHEMBL16367297 | 0.82 | L3MBTL1 (0.40) | L3MBTL1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL16367335 | 0.79 | ATG7 (0.37) | ADORA1ADORA3ADORA2AADORA2BCA1 | |
| SCHEMBL16367320 | 0.78 | ADORA3 (0.41) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5448206 | 0.76 | STAT3 (0.41) | CA1CA9ATG7 | |
| SCHEMBL5452051 | 0.76 | STAT3 (0.41) | CA1CA9ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | L3MBTL1 2029/4885ADORA1 3487/4885ADORA3 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.